HR-5160-119
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.
Sponsored by Christopher Smith (R-NJ)
What it does
This bill would reauthorize the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory through fiscal year 2031. It would increase annual funding for the program from $31,009,000 to $33,009,000 for fiscal years 2027 through 2031 — a roughly $2 million per year increase. It would also extend the cord blood inventory program's authorization deadline from 2026 to 2031.
Who benefits
Patients with blood cancers (leukemia, lymphoma), sickle cell disease, and other blood disorders who depend on cord blood and bone marrow transplants. Racial and ethnic minorities who are statistically underrepresented in donor registries and face greater difficulty finding matched donors. Cord blood banks and transplant centers that receive federal funding. Researchers studying stem cell therapies. Hospitals and medical centers that perform transplants. Future patients who may benefit from an expanded cord blood inventory.
Who is hurt
Taxpayers who bear the cost of the increased appropriation. Competing federal health programs that may face indirect budget pressure. Private cord blood banking companies, which may face a competitive disadvantage if the federally funded public inventory expands. There are no direct regulatory burdens imposed on any group.
Supporters argue
Supporters argue that the C.W. Bill Young Cell Transplantation Program is a proven, life-saving infrastructure that connects patients with matched donors for bone marrow and cord blood transplants — often the only curative option for blood cancers and inherited blood disorders. They contend that the modest $2 million annual funding increase is necessary to maintain and grow the cord blood inventory, particularly to improve match rates for minority patients who are significantly underserved by existing registries, and that a lapse in authorization would disrupt an established network serving thousands of patients annually.
Opponents argue
Opponents argue that reauthorization bills like this one are often passed without rigorous evaluation of whether the program is achieving its goals cost-effectively, and that the funding increase lacks a detailed justification tied to specific performance metrics or unmet inventory targets. They contend that Congress should require a formal program review before extending authorization five more years, and that the absence of accountability measures or outcome benchmarks makes it difficult to assess whether the additional $10 million in total new spending over the authorization period represents the best use of federal healthcare dollars.
Constitutional context
Congress funds this program under the Taxing and Spending Clause (Art. I, §8, cl. 1), which grants broad authority to spend for the general welfare. No significant constitutional challenge is apparent — this is a straightforward reauthorization of an existing, voluntary federal grant program with no mandates on states or individuals.
Checks and balances
Congress holds the appropriations power and sets the funding level; the Department of Health and Human Services administers the program through HRSA; annual appropriations cycles provide ongoing congressional oversight of spending.
Historical precedent
The original Stem Cell Therapeutic and Research Act was enacted in 2005 and has been reauthorized multiple times, most recently in 2020, following the same pattern of extending authorization and modestly adjusting funding levels.